Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 14,834 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 14,834 shares of Celldex Therapeutics, valued at approximately $269,000, marking its new investment in the company during the first quarter.
• Celldex Therapeutics reported a quarterly earnings loss of ($0.81) EPS, missing analysts' estimates, with revenues of $0.70 million, which were below the expected $1.08 million.
• Analysts have mixed outlooks on Celldex, with price targets ranging from $31.00 to $64.00 and an average rating of "Moderate Buy."

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 14,834 shares of the biopharmaceutical company's stock, valued at approximately $269,000.

Other hedge funds also recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after acquiring an additional 871 shares during the period. Tudor Investment Corp ET AL bought a new position in Celldex Therapeutics in the fourth quarter valued at about $822,000. Natixis acquired a new stake in Celldex Therapeutics during the 4th quarter worth approximately $399,000. JPMorgan Chase & Co. grew its holdings in Celldex Therapeutics by 103.3% during the 4th quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company's stock worth $2,162,000 after acquiring an additional 43,470 shares during the last quarter. Finally, Deep Track Capital LP acquired a new position in Celldex Therapeutics in the 4th quarter valued at approximately $38,919,000.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock traded down $0.67 during trading on Friday, reaching $20.55. 422,366 shares of the company traded hands, compared to its average volume of 926,423. The firm has a market capitalization of $1.36 billion, a PE ratio of -7.64 and a beta of 1.22. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The company has a 50 day moving average price of $21.52 and a 200-day moving average price of $20.77.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%. Equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analysts Set New Price Targets

CLDX has been the subject of several analyst reports. UBS Group lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Celldex Therapeutics in a research report on Friday, June 13th. Finally, Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.11.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.